Treatment outcome of tacrine therapy depends on apolipoprotein genotype and gender of the subjects with Alzheimer's disease

Martin Farlow, Debomoy Lahiri, J. Poirier, J. Davignon, L. Schneider, Siu Hui

Research output: Contribution to journalArticle

168 Citations (Scopus)

Abstract

We studied the effects of apolipoprotein E (APOE) genotype and gender on clinical response to tacrine in patients with mild to moderate Alzheimer's disease (AD). We analyzed data from a previously reported 30-week, double- blind, placebo-controlled trial of tacrine, in which APOE genotypes were determined from previously collected plasma samples. Patients were assigned to placebo or tacrine with daily dosages of 80, 120, or 160 mg/day. The outcome measures were Alzheimer's Disease Assessment Scale-Cognitive Component, Clinician Interview Based Impression, Mini-Mental State Examination, and the Caregiver-rated Clinical Global Impression of Change. An intent-to-treat (ITT) analysis of patients with available genotypes (n = 528) did not reveal response differences by genotype, although the effect size was twice as large in the ε2-3 as the ε4 group (-2.62 versus -1.25). The association of treatment effect with APOE genotype varied significantly according to gender (p < 0.002 for ITT; p < 0.05 for evaluables). The treatment effect was larger in the ε2-3 compared with ε4 women (ITT, 4.24 points, p = 0.03; evaluable, 7.20 points, p = 0.01). In contrast, treatment effect size was not different between ε2-3 and ε4 of men with AD. APOE genotype and gender may predict response to tacrine in patients with AD.

Original languageEnglish
Pages (from-to)669-677
Number of pages9
JournalNeurology
Volume50
Issue number3
StatePublished - Mar 1998

Fingerprint

Tacrine
Apolipoproteins
Alzheimer Disease
Genotype
Apolipoproteins E
Therapeutics
Placebos
Caregivers
Outcome Assessment (Health Care)
Interviews

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Treatment outcome of tacrine therapy depends on apolipoprotein genotype and gender of the subjects with Alzheimer's disease. / Farlow, Martin; Lahiri, Debomoy; Poirier, J.; Davignon, J.; Schneider, L.; Hui, Siu.

In: Neurology, Vol. 50, No. 3, 03.1998, p. 669-677.

Research output: Contribution to journalArticle

@article{9d04ca5a1e044d76bdf9b4cfad9f2794,
title = "Treatment outcome of tacrine therapy depends on apolipoprotein genotype and gender of the subjects with Alzheimer's disease",
abstract = "We studied the effects of apolipoprotein E (APOE) genotype and gender on clinical response to tacrine in patients with mild to moderate Alzheimer's disease (AD). We analyzed data from a previously reported 30-week, double- blind, placebo-controlled trial of tacrine, in which APOE genotypes were determined from previously collected plasma samples. Patients were assigned to placebo or tacrine with daily dosages of 80, 120, or 160 mg/day. The outcome measures were Alzheimer's Disease Assessment Scale-Cognitive Component, Clinician Interview Based Impression, Mini-Mental State Examination, and the Caregiver-rated Clinical Global Impression of Change. An intent-to-treat (ITT) analysis of patients with available genotypes (n = 528) did not reveal response differences by genotype, although the effect size was twice as large in the ε2-3 as the ε4 group (-2.62 versus -1.25). The association of treatment effect with APOE genotype varied significantly according to gender (p < 0.002 for ITT; p < 0.05 for evaluables). The treatment effect was larger in the ε2-3 compared with ε4 women (ITT, 4.24 points, p = 0.03; evaluable, 7.20 points, p = 0.01). In contrast, treatment effect size was not different between ε2-3 and ε4 of men with AD. APOE genotype and gender may predict response to tacrine in patients with AD.",
author = "Martin Farlow and Debomoy Lahiri and J. Poirier and J. Davignon and L. Schneider and Siu Hui",
year = "1998",
month = "3",
language = "English",
volume = "50",
pages = "669--677",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Treatment outcome of tacrine therapy depends on apolipoprotein genotype and gender of the subjects with Alzheimer's disease

AU - Farlow, Martin

AU - Lahiri, Debomoy

AU - Poirier, J.

AU - Davignon, J.

AU - Schneider, L.

AU - Hui, Siu

PY - 1998/3

Y1 - 1998/3

N2 - We studied the effects of apolipoprotein E (APOE) genotype and gender on clinical response to tacrine in patients with mild to moderate Alzheimer's disease (AD). We analyzed data from a previously reported 30-week, double- blind, placebo-controlled trial of tacrine, in which APOE genotypes were determined from previously collected plasma samples. Patients were assigned to placebo or tacrine with daily dosages of 80, 120, or 160 mg/day. The outcome measures were Alzheimer's Disease Assessment Scale-Cognitive Component, Clinician Interview Based Impression, Mini-Mental State Examination, and the Caregiver-rated Clinical Global Impression of Change. An intent-to-treat (ITT) analysis of patients with available genotypes (n = 528) did not reveal response differences by genotype, although the effect size was twice as large in the ε2-3 as the ε4 group (-2.62 versus -1.25). The association of treatment effect with APOE genotype varied significantly according to gender (p < 0.002 for ITT; p < 0.05 for evaluables). The treatment effect was larger in the ε2-3 compared with ε4 women (ITT, 4.24 points, p = 0.03; evaluable, 7.20 points, p = 0.01). In contrast, treatment effect size was not different between ε2-3 and ε4 of men with AD. APOE genotype and gender may predict response to tacrine in patients with AD.

AB - We studied the effects of apolipoprotein E (APOE) genotype and gender on clinical response to tacrine in patients with mild to moderate Alzheimer's disease (AD). We analyzed data from a previously reported 30-week, double- blind, placebo-controlled trial of tacrine, in which APOE genotypes were determined from previously collected plasma samples. Patients were assigned to placebo or tacrine with daily dosages of 80, 120, or 160 mg/day. The outcome measures were Alzheimer's Disease Assessment Scale-Cognitive Component, Clinician Interview Based Impression, Mini-Mental State Examination, and the Caregiver-rated Clinical Global Impression of Change. An intent-to-treat (ITT) analysis of patients with available genotypes (n = 528) did not reveal response differences by genotype, although the effect size was twice as large in the ε2-3 as the ε4 group (-2.62 versus -1.25). The association of treatment effect with APOE genotype varied significantly according to gender (p < 0.002 for ITT; p < 0.05 for evaluables). The treatment effect was larger in the ε2-3 compared with ε4 women (ITT, 4.24 points, p = 0.03; evaluable, 7.20 points, p = 0.01). In contrast, treatment effect size was not different between ε2-3 and ε4 of men with AD. APOE genotype and gender may predict response to tacrine in patients with AD.

UR - http://www.scopus.com/inward/record.url?scp=0031943549&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031943549&partnerID=8YFLogxK

M3 - Article

C2 - 9521254

AN - SCOPUS:0031943549

VL - 50

SP - 669

EP - 677

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 3

ER -